drugset / Trial / NCT01198145

Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

NCT01198145

RandomizedParallel-groupDouble-blindSupportive care

Summary

RATIONALE: Sulfasalazine may relieve diarrhea in patients with cancer who are undergoing pelvic radiation therapy. PURPOSE: This randomized phase III trial is studying sulfasalazine to see how well it works in preventing acute diarrhea in patients with cancer who are undergoing pelvic radiation therapy.

Timeline

Start
2011-04
Primary completion
2013-07-22
Completion
2017-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulfasalazine Small molecule 1000 mg Oral

Indications